Your session is about to expire
← Back to Search
Erenumab 70 mg for Migraine
Study Summary
This trial will test whether erenumab is more effective than placebo at reducing the number of days with migraine for people with chronic migraine who have unsuccessfully tried other preventive treatments and have medication overuse headache.
- Migraine
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What other trials have occurred that employed the use of Erenumab 70 mg?
"Erenumab 70 mg was initially investigated at iResearch Savannah, LLC in 2019 and has since seen the completion of 18342 trials. Currently, Meridian, Idaho is home to a copious number of existing studies actively recruiting participants for their research."
Are there any openings in the clinical trial that individuals can join?
"Allegedly, clinicaltrials.gov does not list this trial as presently recruiting participants. It was first posted on October 7th 2019 and last updated on June 17th 2022. However, there are several other trials currently enrolling patients with a total of 282 spots available for prospective volunteers."
In which locales is this clinical trial presently functioning?
"Currently, this research is taking place in 24 different medical centres. Among those are sites based in Meridian, Tampa and Ann Arbor as well as other cities. It would be wise to choose the site closest to you if you decide to take part, so that travelling becomes less of a burden."
Is this a pioneering venture in clinical research?
"Currently, there are 18 ongoing trials of Erenumab 70 mg spanning 179 cities and 32 countries. Since its first Phase 3 study in 2019 sponsored by Amgen, which included 456 patients, a total of 18342 studies have been conducted."
To what extent is participation being sought in this research project?
"At this point, recruitment for the trial has been paused. Originally posted on October 7th 2019 and last edited June 17th 2022, potential participants should seek other clinical trials as there are currently 264 studies enrolling those with migraine and 18 examining Erenumab 70 mg."
Are there any safety concerns related to administering Erenumab 70 mg?
"Despite being a Phase 4 study, our team at Power judged Erenumab 70 mg to be highly safe and awarded it with the maximum score of 3."
Who meets the eligibility requirements for participating in this medical trial?
"This clinical trial seeks 620 people who suffer from migraine to participate. The age range required is 18-99 and the eligibility criteria will be evaluated during a three week screening period, followed by a four week baseline period. To meet the requirements, potential participants must have been dealing with migraines for at least one year prior to starting the study and have experienced treatment failure in regards to preventative treatments."
Is this research study open to adults aged 40 years and older?
"The enrollment requirements for this trial dictate that participants must have reached the age of majority and be under 99 years old. There are 45 trials dedicated to minors, while 192 studies focus on seniors over 65."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
What site did they apply to?
Share this study with friends
Copy Link
Messenger